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SEROPREVALENCE OF T. cruzi INFECTION IN BLOOD DONORS AND CHAGAS CARDIOMYOPATHY 
IN PATIENTS FROM THE COAL MINING REGION OF COAHUILA, MEXICO
José Gerardo MARTÍNEZ-TOVAR(1), Eduardo A. REBOLLAR-TÉLLEZ(2) & Ildefonso FERNÁNDEZ SALAS(2)
SUMMARY
Context and Objective: Chagas disease is considered a worldwide emerging disease; it is endemic in Mexico and the state of 
Coahuila and is considered of little relevance. The objective of this study was to determine the seroprevalence of T. cruzi infection 
in blood donors and Chagas cardiomyopathy in patients from the coal mining region of Coahuila, Mexico. Design and Setting: 
Epidemiological, exploratory and prospective study in a general hospital during the period January to June 2011. Methods: We 
performed laboratory tests ELISA and indirect hemagglutination in three groups of individuals: 1) asymptomatic voluntary blood 
donors, 2) patients hospitalized in the cardiology department and 3) patients with dilated cardiomyopathy. Results: There were three 
levels of seroprevalence: 0.31% in asymptomatic individuals, 1.25% in cardiac patients and in patients with dilated cardiomyopathy 
in 21.14%. Conclusions: In spite of having detected autochthonous cases of Chagas disease, its importance to local public health 
remains to be established as well as the details of the dynamics of transmission so that the study is still in progress.
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INTRODUCTION
Chagas disease or American trypanosomiasis is a neglected public 
health problem in Latin America33. The causative agent of the disease 
is the protozoan Trypanosoma cruzi (Chagas 1909) (Kinetoplastida: 
Trypanosomatidae), which is a flagellate haemoparasite. The life cycle 
of the pathogen involves two hosts corresponding to an insect and to a 
vertebrate. Parasites are transmitted by haematophagous bugs. The vector 
is an insect of the family Reduviidae, and the subfamily Triatominae. The 
main route of infection of T. cruzi to humans is during defecation after 
blood-feeding. Nevertheless, other mechanisms for transmission have been 
documented e.g. blood transfusions from T. cruzi-infected individuals37, 
transplacental route5,27, organ transplantation20,40, breast feeding11,12, 
laboratory accidents15,18, skinning wild animals14 and eating undercooked 
parasitized meat or consuming drink contaminated with triatomine feces44.
The importance of Chagas disease in Mexico was highlighted in the 
national seroprevalence studies reported by VELASCO-CASTREJON 
in 199246 and more recently by NOVELO-GARZA in 201032. In both 
studies it was shown that central and southern Mexico had the highest 
prevalence rates for the presence of positive antibodies against T. cruzi. 
The states with the highest frequencies were Chiapas and Oaxaca with 
5.0% to 4.5% respectively, whereas the mean national seroprevalence 
was estimated in 1.6%.
For the state of Coahuila, the seroprevalence rate, was found to 
range from 0.1% to 0.6%46. Knowledge of Chagas Disease in Coahuila 
is virtually nonexistent and data on prevalence, incidence, transmission 
or vector species in the region have been rarely been referenced8. 
Because very little is known about Chagas disease in the north of 
Mexico and especially in the state of Coahuila, in January 2011 we 
established a research protocol. Its main aim was to provide evidence 
about the prevalence of infection, and to determine the population and 
potential risk factors, as well as to conduct entomological investigations 
to identify potential vectors. During the first phase of this research 
protocol, we established a primary objective which was to determine 
the prevalence of antibodies against Trypanosoma cruzi that occurs 
in the coal mining region of Coahuila. The studied population was 
divided into three groups: (1) asymptomatic blood donors, (2) patients 
admitted to the cardiology department and (3) patients with dilated 
cardiomyopathy. 
METHODS
The work was carried out with blood donors and patients of the 
Hospital General de Zona No. 24 of the Mexican Institute of Social 
Security in Nueva Rosita, Coahuila. This hospital is the main centre 
of medical services in the coal mining region of Coahuila and serves a 
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population of 140,000 inhabitants. Medical facilities possess 82 hospital 
beds and an average of 6,000 discharges per year.
The coal mining region of Coahuila is made up of five municipalities 
which are: Sabinas, San Juan de Sabinas, Múzquiz, Juárez and Progreso. 
The coal mining region is located between latitude 27°51’36’’ - 28o59’24’’ 
N and longitude 101º07’12-101o14’24’’ W and 380 meters above the sea. 
It has a semi-arid climate which means that it is very hot in summer and 
cold in winter17. 
From January through June of 2011 samples were taken in three 
groups of individuals to determine the presence of antibodies to 
Trypanosoma cruzi: (1) blood donors, (2) patients admitted to the 
cardiology department and (3) patients with dilated cardiomyopathy. We 
included all persons who attended as volunteer blood donors, those who 
were admitted to the cardiology hospital department and those reported 
in the clinical diagnosis as dilated cardiomyopathy patients (I42.0 key of 
the International Classification of Diseases tenth edition)34 in the period 
indicated. The only exclusion criterion was refusal to participate in the 
study. The samples of each individual of these groups were analyzed 
to determine the presence of antibodies to T. cruzi. The positive cases 
underwent an epidemiological study that included blood samples taken 
from house cohabitants. Informed consent was requested. The study 
was approved by the Local Bioethics Committee under the registration 
number 2012- 506-25.
The blood donor group included 1615 asymptomatic individuals who 
came voluntarily to donate blood to the blood bank of the same hospital and 
covered eligibility criteria according to the corresponding Mexican Official 
Standard (Norma Oficial Mexicana NOM-003-SSA2-1993, “Provision of 
human blood and blood components for therapeutic purposes”).30
The second group was composed of patients admitted to the 
cardiology hospital department in the same period, these included a 
total of 160 people with various diseases requiring hospital treatment.
The third group was made up of patients with a diagnosis of dilated 
cardiomyopathy. Through the clinical file we found 14 patients with this 
diagnosis. These patients were visited at their homes, and in coordination 
and support of a public health team, blood samples were taken from 
those individuals.
Blood samples were obtained from these patients by a puncture in 
peripheral blood, serum separated by centrifugation at 1200 xg for 10 
minutes, aliquoted in Eppendorf tubes and frozen at -20 °C until analysis.
Two tests were used for the determination of antibodies:
1.  Enzyme linked immunoassay (Biokit - ELISA ChagasWerfen, 
Barcelona, Spain) is an immunoassay method in which microtiter 
wells are coated with four recombinant antigens representing 
immunodominant epitopes of T. cruzi. This test is based on 
the detection of antibody responses to four complementary 
immunodominant epitopes that were discovered by serologic 
expression cloning, by using sera from infected patients. These 
epitopes are expressed as a single recombinant protein, called 
Therapeuticf, consisting of 101 amino acids, including the amino acid 
hexahistidine tag used for purification. This protein is expressed in 
an E. coli expression vector and is purified to a single band on SDS 
page gels36. This procedure was carried out according to Biokit’s 
specifications. The study has a sensitivity of 100% and a specificity 
of 99.24% according to the manufacturer13, 35. 
2.  Indirect haemagglutination (HI), also known as reverse passive 
hemagglutination with Chagatest R (Wiener Laboratory, Rosario, 
Argentina), based on the property of producing antibodies specific 
agglutination in the presence of red blood cells sensitized with the 
corresponding antigens. The procedure was carried out according 
to the manufacturer’s specifications. Titers of 1:16 were considered 
positive29,45.
The enzyme-linked immunoassay was used as a screening test. Those 
samples that were positive in the first instance were subsequently analyzed 
by indirect hemagglutination as a confirmatory test. In accordance with 
the actual guidelines31, the confirmation of the diagnosis of Chagas 
disease is established by at least two different positive serologic tests. 
No other tests were carried out.
In the cases that were found positive samples with both tests, 
we requested them to answer a questionnaire to elaborate on an 
epidemiological study that included medical history, history of blood 
transfusion, travel to endemic areas, chest radiographs, electrocardiogram, 
housing data, risk activities, photographic identification of triatomines 
and blood sampling from cohabitants. The medical history included 
questions on alimentary habits.
In positive cases, a search of triatomines at their home premises was 
conducted. Triatomine bugs were sought within and around the houses. 
RESULTS
The study population had the following characteristics: a total of 
1615 volunteer donors whose ages ranged between 18 and 65 years old. 
It was found that 88% were men (n = 1421) and the remaining 12% were 
women (n = 194), the average age of the sample was 37 years. Patients 
hospitalized in the cardiology department were 56 women (35%) and 104 
men (65%), with a mean age of 69.4 years old. In the group of patients 
with dilated cardiomyopathy there were 14 cases, including eight women 
(54%) and six men (46%) with a mean age of 60.9 years old. Only one 
of the sampled cohabitants was found as positive, a five year old girl. All 
positive cases were reactive for both ELISA and HAI.
The results of this study are summarized in Table 1. A total of 1615 
asymptomatic individuals were analyzed as potential blood donors, five 
were positive. Out of 160 patients admitted to the cardiology department 
we found two positive cases. Finally, in the third group of 14 patients 
with dilated cardiomyopathy, we found that three of them were positive. 
There was a positive sample derived from the study of co-inhabitants. 
Seroprevalence levels were found to be 0.31%, 1.25% and 21.14% in 
asymptomatic individuals, cardiac patients and in patients with dilated 
cardiomyopathy, respectively. Table 2 shows the individual characteristics 
of positive cases. Additionally, the geographic distribution of cases in 
the study area is shown in Figure 1.
The epidemiological survey of positive cases revealed that none had 
been born outside the studied area nor had any traveled to an endemic 
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area of American trypanosomiasis. The houses of individuals who tested 
positive were built of block and cement. The questionnaire that included 
a question on alimentary habits did not reveal any answers that may 
indicate oral contamination. At the time of our entomological survey, no 
triatomines were found inside or around the home premises. Only one of 
the positive cases of dilated cardiomyopathy had had a blood transfusion 
two years before this study and corresponded to a 60-year-old female 
who has lived in this area all her life. The transfusion was conditioned 
by anemia secondary to metrorrhagia.
Socioeconomic status is about average lower middle class, none 
were considered to be living in a state of poverty. Positive cases were 
questioned about risk activities such as going to camps, sleeping 
outdoors, as well as the consumption of wild animals and so forth and the 
responses were all negative. People were also shown actual-size pictures 
of triatomines for identification and we recorded that none of them were 
able to recognize the vector correctly. 
DISCUSSION
The northeast region of Mexico (states of Coahuila, Nuevo León 
and Tamaulipas) is usually not considered as part of the endemic area of 
Chagas disease in Mexico and for these reasons the disease has largely been 
neglected by the health sector. In a study carried out by GALAVÍZ-SILVA 
et al. (2009)13 a seroprevalence of 2.8 % antibodies against T. cruzi was 
found in blood donors in a hospital of the state of Nuevo León. Regarding 
the state of Coahuila, there has been virtually no diagnosis in Chagas for 
the past 20 years. The national study of VELASCO-CASTREJON et al. 
Fig. 1 - Above, a map showing the five municipalities that comprised the coal mining regions 
in the state of Coahuila. The insert in the upper right corner, represents (black filled shapes) 
the location of the state of Coahuila in Mexico, as well as the proportion of the coal mining 
regions in the state of Coahuila. Below, geographical location of Chagas disease cases in the 
coal mining region of Coahuila in the period January to June 2011. The image was taken from 
Google Earth®. The blue balloons correspond to the location of the cases. The red balloon 
represents a positive case found during the epidemiological study.
Table 1
Seroprevalence results found in the coal mining region of Coahuila in relation 
with the different groups analyzed




Blood tranfusion center 1615 5 0.31
Cardiology Hospital Service 160 2 1.25
Cardiomyopathy 14 3 21.14
Table 2
Main epidemiological characteristics of positive cases with T. cruzi positive serological results Coahuila coal mining region
Progressive 







1 42 M Transfusion center Asymptomatic Negative Negative Negative
2 53 M Transfusion center Asymptomatic Negative Negative Negative
3 35 M Transfusion center Asymptomatic Negative Negative Negative
4 26 M Transfusion center Asymptomatic Negative Negative Negative
5 25 M Transfusion center Asymptomatic Negative Negative Negative
6 76 M Hospital  Cardiac Failure Negative Negative Negative
7 60 F Hospital Cardiac Failure Negative Negative Negative
8 76 M Home Dilated Cardiomyopathy Negative Negative Negative
9 60 F Home Dilated Cardiomyopathy Positive 2 years ago Negative Negative
10 61 F Home Dilated Cardiomyopathy Negative Negative Negative
11 5 F Home Asymptomatic Negative Negative Negative
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in 1992 in a sample of 1976 people, found a prevalence of 0.1 to 1:32 
dilution using hemagglutination and indirect immunofluorescence46. To the 
best of our knowledge, no other study has been carried out in the state of 
Coahuila, and therefore this paper represents the first evidence that there is 
a suggested risk of infection of T. cruzi among the human population. The 
work of NOVELO-GARZA, in 2010 revised the responses to antibodies 
against T. cruzi using the ELISA test carried out among blood donors in 
the Mexican Social Security Institute and reported that in a population of 
230,074 they found a seroprevalence of 0.406 %. For the state of Coahuila 
that National survey included 4611 persons of which 10 were positive for an 
overall rate of 0.217 in the state. If the state is divided into north and south 
regions, leaving the towns of Monclova, Nueva Rosita and Piedras Negras 
as north, then it can be seen that this estimate increases to 0.37 %, which 
would be a similar estimate to that found in this study. In the city Nueva 
Rosita which is the center of the coal mining region, the seroprevalence 
was found to be 0.77 %, and this corresponds to a single case in a sample 
of only 129 people32.
The laboratory diagnosis of Chagas disease depends on the clinical 
stage. It is known that in acute cases it is only possible to identify the 
etiologic agent, whereas an indeterminate and chronic diagnosis is based 
on the presence of antibodies against the parasite protozoon T. cruzi 
in sera of infected individuals. These antibodies are mostly detected 
using different serological tests, the most widely used are the indirect 
hemagglutination (IHA), enzyme-linked immunosorbentassay (ELISA) 
and indirect immunofluorescence (IIF), due to the easy implementation, 
low cost and good results in terms of specificity and sensitivity. Based on 
several protocols, it is considered to be a case of Chagas disease when 
the blood samples of an individual give positive results from at least two 
different serologic tests21,38,43.
Most recently the polymerase chain reaction has been used to detect 
T. cruzi DNA in tissues samples from necropsies and additionally, with 
this technique it has been possible to determine the number of copies as a 
way to establish the parasite load in these patients22. The use of molecular 
techniques to confirm the diagnosis of Chagas disease in a daily clinical 
practice is still out of reach of most health institutions in Mexico6. In 
our study, confirmation of positive samples by molecular techniques was 
not considered at this stage because the main objective was to detect 
seroprevalences in a particular population using the resources provided 
by the hospital of Instituto Mexicano del Seguro Social (IMSS). 
In the present study we found a seroprevalence of 0.31%, 1.25% and 
21.14% for the blood donor (asymptomatic) group, hospitalized cardiac 
patients and patients with dilated cardiomyopathy respectively. These 
figures show that the coal mining region of Coahuila is an area in which 
there is circulation of T. cruzi although traditionally it was considered non-
endemic region. This data also suggests that Chagas disease may represent 
a cause for cardiomyopathy. It is likely that many cases are not recognized 
by the health institutions. Nonetheless, our entomological surveys 
were limited; we found that in those communities there is basically no 
knowledge about the vectors and/or transmission mechanisms. Lack 
of knowledge on vectors or transmission mechanisms represents a 
shortcoming in the implementation of any prevention program. As was 
previously mentioned in the results, none of the positive cases were 
able to identify the insect vector and we did not found triatomine bugs 
during the search inside and around their houses. The failure to find 
triatomines in the houses does not necessarily indicate their absence. 
It is possible that insects might not have been properly detected during 
searches or that perhaps they have been conducted at a time of the year 
when their presence is scarce. It is also possible to consider that there 
is a transmission cycle well outside houses, which may be conditioned 
by the migration of vectors between suburban and wild environments24. 
We suggest that more systematic and thorough entomological studies 
are required to evaluate the transmission and risk potential of triatomine 
vectors occurring in the region.
An extradomiciliary cycle of T. cruzi can be carried out and maintained 
in vertebrates other than man, including domestic animals such as pet 
dogs3. In the United States of America (USA), and particularly in the 
state of Texas, several vertebrate species (armadillos, coyotes, raccoons, 
opossums and rats of the genus Neotoma) have been documented as having 
tested positive for the infection with T. cruzi42. Until recently, in the USA 
only seven indigenous cases of Chagas disease have been reported (four 
in Texas, one in Tennessee, one in California and one in Louisiana)4,10. 
In addition to the above cases, CANTLEY et al., cited a study “The 
United Sates Trypanosoma cruzi Infection Study” (USTC), which made 
possible infection screening of blood donors and found that an initial 
sample of 29 million, 1084 tested positive for antibodies T. cruzi and after 
performing exclusion criteria for a follow-up study, it was determined that 
15 indigenous cases were confirmed by tests conducted by the Centers for 
Disease Control (CDC) and also added a case from the state of Mississippi. 
In the above-mentioned study there were 15 new autochthonous Chagas 
cases7. These new cases certainly indicate that the prevalence of infection 
with T. cruzi in the USA may in fact be an underestimation of the actual 
disease prevalence and we suggest that something similar may well be 
happening in northern Mexico, where Chagas disease is still considered 
unimportant by national health programs.
It should be noted that the U.S.-Mexico border region, shares some 
socio-cultural aspects, such as significant migratory movement and the 
presence of some common parasitic diseases, including Chagas disease16. 
Furthermore, it has been reported that in Texas there have been seven 
major species of triatomine19 of which Triatoma gerstaeckeri, Triatoma 
lecticularia and Triatoma sanguisuga are considered fairly common and 
have extensive geographic distributions including many northern states in 
northeastern Mexico42. Many Texas counties that are bordering Mexico 
have records of the presence of bugs infected with T. cruzi19. It remains to 
be seen which other triatomine species exist in the state of Coahuila and 
what the population abundance, seasonality, infection rate and vectorial 
capacity are. Studies conducted in Nuevo Leon, a Mexican State next 
to Coahuila, reported T. cruzi infection in collected domestic and wild 
Triatoma gerstaeckeri made in municipality of General Teran23,26. A 
recent study carried out by our research group, reported the presence of 
native triatomines T. gerstaeckeri and T. rubida in the north of Coahuila 
near to the coal region, which may represent another risk factor for local 
Chagas disease infection25. 
Regarding the disease, at this stage it can be said that there are 
several elements that indicate the presence of autochthonous cases of 
Chagas. First of all, we have the confirmation of eleven positive samples 
by two different serological tests and their clinical histories. Secondly, 
the fact that none of the individuals who tested positive had travelled to 
high endemicity areas, restricts the possibility of acquiring the infection 
elsewhere. Thirdly, we have shown in another publication the presence 
of two triatomine bugs in Coahuila (i.e. T. gerstaeckeri and T. rubida), 
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which have been recognized as species of medical importance in the USA. 
Fourthly, there are some paleoparasitological reports2,39 that demonstrate 
that ancient mummies (aged circa 1,000 years) found by the Rio Grande 
(Rio Bravo) border between Coahuila and Texas were indeed infected 
with T. cruzi. All the above evidence led us to believe that there is an 
as yet unraveled transmission cycle of T. cruzi in the region and that 
therefore, more detailed studies are required to fully assess the impact 
and magnitude of risk to the human population. 
Recognizing the problem of Chagas disease by health authorities 
and inhabitants of this particular region is a very important aim to be 
achieved and nowadays much work has yet to be carried out in these areas. 
There is also the problem of the treatment since there is no consensus 
about the correct or optimal management of indeterminate and chronic 
cases1.  Until now there is no effective treatment for the indeterminate 
and chronic cases.  Although there are studies on developing alternative 
autologous stem cell treatment and experimental drugs, its management 
has been limited to the treatment of clinical presentation, e.g. heart failure 
or arrhythmias28.  It is important at the time of detection of indeterminate 
cases the decision of treatment in order to prevent the chronic condition 
leading to high costs and mortality in health47.
CONCLUSION
In this study, we report the presence of autochthonous cases of 
Chagas disease in the coal zone of Coahuila, which highlights the 
importance of screening studies and finding cases more frequently and 
with greater geographic coverage. It is very important to disseminate 
information about the disease, the parasite and its insect vector between 
inhabitants living in risk areas. With extensive preventative actions the 
epidemiological costs will be lower and patient expectations about 
treatment will be better. Therefore we stress the urgent need to continue 
with more studies to determine the extent of the Chagas problem in the 
state and in the northeastern region of the country.
RESUMO
Soroprevalência da infecção pelo T. cruzi em doadores de sangue 
e cardiomiopatia chagásica em pacientes da região carbonífera de 
Coahuila, México
Contexto e Objetivo: A doença de Chagas é mundialmente 
considerada uma doença emergente, é endêmica no México e no estado 
de Coahuila e considerada de pouca relevância. O objetivo do estudo foi 
determinar a soroprevalência da infecção pelo T. cruzi em doadores de 
sangue e cardiomiopatia chagásica em pacientes da região carbonífera 
de Coahuila, México. Desenho e Local: Estudo epidemiológico, 
exploratório e prospectivo em um hospital geral no período de janeiro a 
junho de 2011. Métodos: Foram realizados testes de laboratório ELISA 
e hemoglutinação indireta em três grupos de indivíduos: 1) doadores de 
sangue voluntários assintomáticos, 2) pacientes internados na área de 
cardiologia e 3) pacientes com cardiomiopatia dilatada. Resultados: 
Foram achados três níveis de soroprevalência: 0,31% em indivíduos 
doadores de sangue assintomáticos, 1,25% em pacientes cardiopatas e, em 
pacientes com cardiomiopatia dilatada 21,14%. Conclusão: Detectamos 
casos autóctones de doença de Chagas em área considerada não endêmica. 
Deve ser determinada sua importância na saúde pública regional e local, 
para estabelecer os detalhes do mecanismo de transmissão. O estudo 
ainda está em desenvolvimento.
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